Case Report
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 14, 2007; 13(22): 3137-3140
Published online Jun 14, 2007. doi: 10.3748/wjg.v13.i22.3137
Table 1 Main characteristics and course of HCV-infected patients with VKH-like disease
Case 1Case 2Case 3
Age (yr)435142
SexFFM
HCV genotype liver biopsy (Metavir)1311
A1F2A1F2A3F1
Anti-HCV therapyPEG-IFN α-2b + RibavirinPEG-IFN α-2b + RibavirinPEG-IFN α-2b + Ribavirin
Interval before first ocular manifestations24 mo3 mo4 mo
Ocular manifestations-Visual acuity 20/200 OS-Bilateral vision loss-Bilateral vision loss
-Macular edema and a bilateral serous retinal detachment.-Bilateral uveitis, major papillar and retinal edema-Episcleritis and bilateral uveitis
Retinal fluorescein angiographyPin-points and bilateral serous retinal and pigmented epithelium detachments, suggestive of a Vogt-Koyanagi-Harada like [VKH] disease
Therapeutic management-PEG-IFN and ribavirin disruption-PEG-IFN and ribavirin disruption-PEG-IFN and ribavirin disruption
-Methylprednisolone IV and per os- Methylprednisolone IV and per os- Methylprednisolone IV and per os
Course-Complete recovery under low dose steroids (< 10 mg/d)-Low improvement of ocular lesions-Partial improvement of ocular lesions
-Steroids were stopped after one year of treatment without ocular relapse.-Cortico-dependency > 25 mg/d-Cortico-dependency > 25 mg/d
-Failure of cyclosporine course-Re-introduction of PEG-IFN and ribavirin 5 mo later3
-Introduction of azathioprine-Full recovery of ocular manifestations 10 mo after IFN was reintroduced
Table 2 Main features of HCV-infected patients with intraocular vascular complications under PEG-IFN and ribavirin treatment
Main featuresCase 4Case 5Case 6Case 7Case 8
Age (yr)5170554040
SexMMFMM
HCV genotype12
Liver biopsy (Metavir)NDF4A2F1A2F2F4 (clinical cirrhosis)
AntecedentsSarcoidosisArterial hypertension-Splenic lymphoma with villous lymphocytesHypertension with past hypertensive retinopathy
SmokingMixed cryoglobulin- associated glomerulonephritis
Severe arterial hypertension
Dyslipidemia, smoking
Anti-HCV therapyPEG-IFN α-2b + RibavirinPEG-IFN α-2b + RibavirinPEG-IFN α-2b + RibavirinStandard IFN α-2b + ribavirinStandard IFN α-2b + Ribavirin
Interval before first ocular manifestations7 mo5 mo6 mo18 mo6 mo
Ocular manifestations-Initial visual acuity: OD (< 20/200), OS (20/20)-OD vision loss (20/200 OD; 20/20 OS)-Bilateral vision loss (20/400 OD, 20/80 OS)-Visual acuity OS: 10/10; OD: < 20/200-Bilateral vision loss (20/64 P2 OD, 20/200 OS)
-Papillar edema, macular edema and retinal hemorrhages-Bilateral macular edema and retinal hemorrhages
-Cotton wool spots-Cotton-wool spots (IFN-α-induced retinopathy) (Figure 1A and B)
DiagnosisCentral retinal vein occlusion ODCentral retinal vein occlusion ODAcute anterior ischemic optic neuritisCentral retinal artery occlusion ODExsudative hypertensive and IFN -induced retinopathy
Treatment-Withdrawal of PEG-IFN and ribavirin-Withdrawal of PEG-IFN and ribavirin-Withdrawal of PEG-IFN and ribavirin-Withdrawal of standard IFN and ribavirin-Withdrawal of standard IFN and ribavirin
-Steroids and IV heparin-Steroids, IV heparin and aspirin-Steroids-Steroids and IV heparin-Better control of hypertension (nadolol, benazepril)
Course-6 mo later, radiary neurotomy-2 mo later, radiary neurotomy-At the end of follow-up, severe visual impairment (< 20/400 OD; 20/80 OS)-4 mo later, slow improvement (20/64 OD)-2 mo later, significant improvement of the visual acuity (20/40 OD; 20/40 OS)
-At the end of follow-up, definitive loss of vision OD (< 20/200)-At the end of follow-up, definitive vision loss OD-Died of severe sepsis 5 mo later-Introduction of PEG- IFN α-2b and Ribavirin without recurrence after more than 1 yr follow-up